A



B

Treatment	SUCRA	PrBest	Mean rank
DPP4i+SGLT2i	92.4	75.1	1.8
Placebo	77.8	8.0	3.2
DPP4i	70.9	1.8	3.9
TZD	55.9	1.6	5.4
SGLT2i	52.8	0.3	5.7
Met+TZD	46.5	10.6	6.4
GLP-1RA	45.1	0.8	6.5
Met	44.4	0.0	6.6
Met+DPP4i	35.2	0.2	7.5
Met+SU	19.0	1.6	9.1
SU	10.1	0.0	10

Supplementary Fig. 7. Network geometry (A), rank test (B), the results of network and pairwise meta-analysis (C) for odds ratios of hypoglycemia risk of antidiabetic treatments. (A) The global test for inconsistency yielded a *P* value of 0.9385, indicating no evidence of inconsistency in the network. (B) The table presents the results of the network rank test (surface under the cumulative ranking curve [SUCRA], probability of being the best [PrBest], mean rank) for different antidiabetic treatments, ordered by mean rank. (C) Network (upper right side) and pairwise (lower left side) meta-analytic results are depicted for odds ratios of odds ratios of hypoglycemia risk of antidiabetic treatments. The outcome of meta-analysis is expressed as effect size with 95% credible intervals in the case of network meta-analysis and 95% confidence intervals in the case of pairwise meta-analysis. Each value and interval refer to the efficacy of the top-row treatment compared to the left column. The order of antidiabetic treatments in this league table is presented in order of the mean rank results. TZD, thiazolidinedione; SGLT2i, sodium-glucose cotransporter-2 inhibitor; GLP-1RA, glucagon-like peptide-1 receptor agonist; DPP4i, dipeptidyl peptidase-4 inhibitor; Met, metformin; SU, sulfonylurea. [a]Results indicate statistical significance.

(*Continued to the next page*)

Supplementary Fig. 7. Continued

C

	DPP4i+SGLT2i	Placebo	DPP4i	TZD	SGLT2i	Met+TZD	GLP-1RA	Met	Met+DPP4i	Met+SU	SU
DPP4i+SGLT2i	DPP4i+SGLT2i	4.97 (0.18–136.0)	6.08 (0.25–150.2)	15.10 (0.27–840.6)	11.29 (0.62–205.2)	18.12 (0.07–4997.0)	16.85 (0.48–596.6)	17.60 (0.32–973.2)	25.60 (0.42–1548.9)	103.12 (0.55–19460.3)	85.4[a] (1.54–4741.2)
Placebo		Placebo	1.22 (0.54–2.75)	3.04 (0.24–39.1)	2.27 (0.31–16.6)	3.64 (0.03–394.9)	3.39 (0.89–12.9)	1.04 (0.06–18.5)	5.15 (0.35–75.4)	20.73 (0.30–1415.1)	17.2[a] (1.34–220.3)
DPP4i	0.17 (0.01–4.07) I^2=0.0% 1 study	0.83 (0.38–1.81) I^2=0.0% 5 studies	DPP4i	2.48 (0.22–28.0)	1.86 (0.30–11.4)	2.98 (0.03–301.1)	2.77 (0.58–13.2)	2.90 (0.26–32.3)	4.21 (0.33–54.5)	16.97 (0.27–1070.5)	14.0[a] (1.25–157.9)
TZD				TZD	0.75 (0.04–15.5)	1.20 (0.02–61.8)	1.12 (0.06–19.9)	0.41 (0.04–3.8)	1.70 (0.70–4.11)	6.83 (0.23–200.2)	5.65[a] (4.64–6.89)
SGLT2i	0.09 (0.01–1.61) I^2=0.0% 1 study	1.05 (0.42–2.66) I^2=0.0% 5 studies	0.60 (0.16–2.24) I^2=0.0% 3 studies		SGLT2i	1.60 (0.01–228.7)	1.49 (0.14–16.4)	0.84 (0.05–15.2)	2.27 (0.10–52.3)	9.13 (0.10–842.9)	7.56 (0.37–155.8)
Met+TZD						Met+TZD	0.93 (0.01–121.4)	0.97 (0.02–49.7)	1.41 (0.03–79.2)	5.69 (0.03–1011.6)	4.71 (0.09–241.9)
GLP-1RA		0.30 (0.08–1.12) I^2=0.0% 3 studies					GLP-1RA	1.80 (0.10–33.2)	1.52 (0.08–30.4)	6.12 (0.07–512.7)	5.06 (0.28–90.1)
Met			0.35 (0.03–3.86) 2 studies	1.05 (0.48–2.25) I^2=48.8% 2 studies		1.03 (0.02–52.6) I^2=0.0% 1 study		Met	1.45 (0.62–3.42)	5.86 (0.20–170.4)	0.28 (0.02–3.60)
Met+DPP4i								0.69 (0.29.1.62) I^2=0.0% 1 study	Met+DPP4i	4.03 (0.15–104.9)	3.33[a] (1.39–8.00)
Met+SU									0.25 (0.01–6.45) I^2=0.0% 1 study	Met+SU	0.83 (0.03–24.20)
SU				0.20[a] (0.12–0.31) I^2=38.7% 2 studies			0.11[a] (0.07–0.18) I^2=0.0% 1 study	0.21[a] (0.17–0.25) I^2=0.0% 2 studies			SU